Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.

被引：0
|
作者：
Caffo, Orazio
De Giorgi, Ugo
Ferra, Francesco
Donini, Maddalena
Facchini, Gaetano
Maruzzo, Marco
Tucci, Marcello
Conteduca, Vincenza
Maines, Francesca
Rossi, Lorena
Veccia, Antonello
Galligioni, Enzo
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[3] Osped S Vincenzo, Dept Med Oncol, Taormina, Italy
[4] Ist Ospitalieri Cremona, Cremona, Italy
[5] Ist Nazl Tumori Fdn G Pascale IRCCS, Med Oncol 1Div, Dept Urogynaecol Oncol, Naples, Italy
[6] IRCCS, Dept Clin & Expt Oncol, Med Oncol 1, IOV, Padua, Italy
[7] AOU San Luigi Gonzaga, Dept Oncol, Orbassano, TO, Italy
[8] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.326
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
326
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.
    Lavallee, Luke
    Morash, Chris
    Saad, Fred
    Yip, Steven
    Kapoor, Anil
    Kolinsky, Michael Paul
    Pouliot, Frederic
    Antebi, Elie
    Drachenberg, Darrel
    Ferrario, Cristiano
    Gotto, Geoffrey
    Hamilton, Robert James
    Ko, Jenny J.
    Noonan, Krista
    So, Alan
    Malone, Shawn
    Zardan, Anousheh
    Chi, Kim N.
    Hotte, Sebastien J.
    Niazi, Tamim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [13] Acitivity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
    Caffo, Orazio
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Basso, Umberto
    Alesini, Daniele
    Tucci, Marcello
    Ortega, Cinzia
    Verderame, Francesco
    Procopio, Giuseppe
    Lo Re, Giovanni
    Campadelli, Enrico
    Omarini, Claudia
    Donini, Maddalena
    Morelli, Franco
    Zucali, Paolo A.
    Sartori, Donata
    Conteduca, Vincenza
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [14] Dexamethasone in pretreated men with metastatic castration-resistant prostate cancer (mCRPC): A prospective study.
    Baciarello, Giulia
    Hamilou, Zineb
    Chebib, Ralph
    Albiges, Laurence
    Fuerea, Alina
    Loriot, Yohann
    Massard, Christophe
    Colomba, Emeline
    Di Palma, Mario
    Escudier, Bernard
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [15] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [16] A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.
    Gonzalez, Francisco
    Kodagali, Rohit
    Tung, Teresa
    Masoud, Mohamed
    Rajadhyaksha, Viraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [17] Oral cyclophosphamide (Cyc) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort from a tertiary public cancer center in Brazil.
    Shinkado, Yumi Ricucci
    Labanda, Diana Del Cisne Pineda
    Polho, Gabriel Berlingieri
    Contado, Gustavo Alves
    Crusoe, Nathalia de Souza Del Rey
    Horita, Vivian
    Martins, Joao Carlos Resende
    de Freitas, Guilherme Fialho
    Muniz, David Queiroz Borges
    Mota, Jose Mauricio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 150 - 150
  • [18] Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tran, Eli
    Jani, Chinmay
    Zhang, Nicole
    Tsai, Jill
    Pan, Elizabeth
    Panian, Justine
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 205 - 205
  • [19] Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gebrael, Georges
    Jo, Yeonjung
    Hage Chehade, Chadi
    Ozay, Zeynep Irem
    Sayegh, Nicolas
    Ostrowski, Micah
    Campbell, Patrick
    Anderson, Ethan
    Nordblad, Blake
    Galarza Fortuna, Gliceida M.
    Mathew Thomas, Vinay
    Riaz, Irbaz Bin
    Graf, Ryon P.
    Guha, Avirup
    Maughan, Benjamin L.
    Roy, Soumyajit
    Antonarakis, Emmanuel S.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [20] ORAL METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR DOCETAXEL THERAPY
    Barroso-Sousa, R.
    Chaves, A. C. R.
    Fonseca, L. G.
    De Castro, G., Jr.
    Dzik, C.
    Hoff, P. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 308
12345